Reverse Payment Patent Settlements in the Pharmaceutical Sector and Competition Law – Do Lundbeck and Actavis Help to Bridge the Views Across the Atlantic Regarding the Delayed Market Entry of Cheaper, Generic Medicines?

International and Comparative Law Review - Poland
doi 10.1515/iclr-2016-0056
Full Text
Abstract

Available in full text

Categories
Law
Date
Authors
Publisher

Walter de Gruyter GmbH

Related search

Anticompetitive Patent Settlements and the Supreme Court's Actavis Decision

SSRN Electronic Journal
2013English

Would the Per Se Illegal Treatment of Reverse Payment Settlements Inhibit Generic Drug Investment?

Journal of Competition Law and Economics
LawEconometricsEconomics
2012English

PHP79 Stakeholders's Views Regarding the Impact of Financial Crisis on the Pharmaceutical Market in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

Do Entry Conditions Vary Over Time? Entry and Competition in the Broadband Market: 1999-2003

SSRN Electronic Journal
2005English

Competition, Syndication, and Entry in the Venture Capital Market

SSRN Electronic Journal
2013English

Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration

2007English

Reverse Innovation and Reverse Technology Transfer: From Made in China to Discovered in China in the Pharmaceutical Sector

Management international
2018English

Analysis of the Pharmaceutical Market of Medicines With the Immunomodulatory Activity in Ukraine

Socìalʹna farmacìâ v ohoronì zdorov'â
2018English

Patents and Public Health in France. Pharmaceutical Patent Law In‐the‐making at the Patent Office Between the Two World Wars

History and Technology
Philosophy of ScienceHistory
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy